Published in Drug Saf on January 01, 2003
Multiple sclerosis patients' benefit-risk preferences: serious adverse event risks versus treatment efficacy. J Neurol (2009) 1.67
Type I IFN receptor controls activated TYK2 in the nucleus: implications for EAE therapy. J Neuroimmunol (2012) 0.90
IFN signaling: how a non-canonical model led to the development of IFN mimetics. Front Immunol (2013) 0.87
Presentation and outcomes with clinically apparent interferon beta hepatotoxicity. Dig Dis Sci (2013) 0.86
Acute hepatitis secondary to interferon beta-1a in multiple sclerosis. J Neurol (2005) 0.85
Short peptide type I interferon mimetics: therapeutics for experimental allergic encephalomyelitis, melanoma, and viral infections. J Interferon Cytokine Res (2014) 0.81
The role of a non-canonical JAK-STAT pathway in IFN therapy of poxvirus infection and multiple sclerosis: An example of Occam's Broom? JAKSTAT (2013) 0.81
Early stage and long term treatment of multiple sclerosis with interferon-beta. Biologics (2009) 0.81
Review of the clinical evidence for interferon beta 1a (Rebif) in the treatment of multiple sclerosis. Neuropsychiatr Dis Treat (2008) 0.80
Robust Oncolytic Virotherapy Induces Tumor Lysis Syndrome and Associated Toxicities in the MPC-11 Plasmacytoma Model. Mol Ther (2016) 0.78
Risk stratification and mitigationin multiple sclerosis. Mult Scler Relat Disord (2014) 0.78
Comparative tolerance of IFN beta-1a regimens in patients with relapsing multiple sclerosis. The EVIDENCE study. J Neurol (2005) 0.76
A murder mystery in the liver: who done it and how? J Clin Invest (2016) 0.76
Hepatic injury, liver monitoring and the beta-interferons for multiple sclerosis. J Neurol (2004) 0.75
Delayed Liver Function Impairment Secondary to Interferon β-1a Use in Multiple Sclerosis. Case Rep Neurol (2013) 0.75
Risk Factors for Poor Adherence to Betaferon® Treatment in Patients with Relapsing-Remitting Multiple Sclerosis or Clinically Isolated Syndrome. PLoS One (2016) 0.75
Importance of benefit-to-risk assessment for disease-modifying drugs used to treat MS. J Neurol (2004) 0.75
An Autopsy Case of Fulminant Hepatitis in a Patient with Multiple Sclerosis Treated by Interferon-Beta-1a. Intern Med (2017) 0.75
c-Jun N-terminal kinase plays a major role in murine acetaminophen hepatotoxicity. Gastroenterology (2006) 3.76
Neutrophil depletion protects against murine acetaminophen hepatotoxicity. Hepatology (2006) 3.70
Aminotransferase elevations in healthy adults receiving 4 grams of acetaminophen daily: a randomized controlled trial. JAMA (2006) 3.49
Betaine decreases hyperhomocysteinemia, endoplasmic reticulum stress, and liver injury in alcohol-fed mice. Gastroenterology (2003) 3.18
Role of JNK translocation to mitochondria leading to inhibition of mitochondria bioenergetics in acetaminophen-induced liver injury. J Biol Chem (2008) 3.08
Clinical risk factors for portopulmonary hypertension. Hepatology (2008) 2.62
Innate immune system plays a critical role in determining the progression and severity of acetaminophen hepatotoxicity. Gastroenterology (2004) 2.26
Outcome of acute idiosyncratic drug-induced liver injury: Long-term follow-up in a hepatotoxicity registry. Hepatology (2006) 2.12
Drug-induced liver injury. Drug Saf (2007) 1.99
A retrospective analysis of the potential impact of IgG antibodies to agalsidase beta on efficacy during enzyme replacement therapy for Fabry disease. Mol Genet Metab (2008) 1.94
Predominant role of sterol response element binding proteins (SREBP) lipogenic pathways in hepatic steatosis in the murine intragastric ethanol feeding model. J Hepatol (2006) 1.89
Sensitivity of the 2-oxoglutarate carrier to alcohol intake contributes to mitochondrial glutathione depletion. Hepatology (2003) 1.72
Hyperhomocysteinemia, endoplasmic reticulum stress, and alcoholic liver injury. World J Gastroenterol (2004) 1.68
Effect of glutathione depletion on sites and topology of superoxide and hydrogen peroxide production in mitochondria. Mol Pharmacol (2003) 1.62
Mechanisms of liver injury. III. Role of glutathione redox status in liver injury. Am J Physiol Gastrointest Liver Physiol (2006) 1.62
ASMase is required for chronic alcohol induced hepatic endoplasmic reticulum stress and mitochondrial cholesterol loading. J Hepatol (2013) 1.61
ER stress: can the liver cope? J Hepatol (2006) 1.58
c-Jun N-terminal kinase (JNK)-dependent acute liver injury from acetaminophen or tumor necrosis factor (TNF) requires mitochondrial Sab protein expression in mice. J Biol Chem (2011) 1.57
Glutathione in liver diseases and hepatotoxicity. Mol Aspects Med (2008) 1.55
Serum alanine aminotransferase in skeletal muscle diseases. Hepatology (2005) 1.54
Hepatic mitochondrial glutathione: transport and role in disease and toxicity. Toxicol Appl Pharmacol (2005) 1.54
Acetaminophen hepatoxicity: what do we know, what don't we know, and what do we do next? Hepatology (2004) 1.51
Impact of hepatopulmonary syndrome on quality of life and survival in liver transplant candidates. Gastroenterology (2008) 1.50
The contribution of endoplasmic reticulum stress to liver diseases. Hepatology (2011) 1.50
Role of S-adenosylmethionine, folate, and betaine in the treatment of alcoholic liver disease: summary of a symposium. Am J Clin Nutr (2007) 1.49
Role of CHOP in hepatic apoptosis in the murine model of intragastric ethanol feeding. Alcohol Clin Exp Res (2005) 1.49
Genetic risk factors for portopulmonary hypertension in patients with advanced liver disease. Am J Respir Crit Care Med (2009) 1.44
Effect of recombinant human growth hormone on exercise capacity in patients with HIV-associated wasting on HAART. AIDS Read (2005) 1.40
Immune-mediated drug-induced liver disease. Clin Liver Dis (2002) 1.38
Regulation of mitochondrial glutathione redox status and protein glutathionylation by respiratory substrates. J Biol Chem (2010) 1.37
Phenotypic characterization of idiosyncratic drug-induced liver injury: the influence of age and sex. Hepatology (2009) 1.35
Role of innate immunity in acetaminophen-induced hepatotoxicity. Expert Opin Drug Metab Toxicol (2006) 1.35
Role of TNF-alpha in ethanol-induced hyperhomocysteinemia and murine alcoholic liver injury. Hepatology (2004) 1.31
Patient outcomes in the GHMonitor: the effect of delivery device on compliance and growth. Pediatr Endocrinol Rev (2005) 1.24
Liver-specific loss of glucose-regulated protein 78 perturbs the unfolded protein response and exacerbates a spectrum of liver diseases in mice. Hepatology (2011) 1.23
Silencing glycogen synthase kinase-3beta inhibits acetaminophen hepatotoxicity and attenuates JNK activation and loss of glutamate cysteine ligase and myeloid cell leukemia sequence 1. J Biol Chem (2010) 1.20
Pregnancy outcomes in multiple sclerosis following subcutaneous interferon beta-1a therapy. Mult Scler (2011) 1.19
Mechanisms for sensitization to TNF-induced apoptosis by acute glutathione depletion in murine hepatocytes. Hepatology (2003) 1.19
Redox regulation of tumor necrosis factor signaling. Antioxid Redox Signal (2009) 1.18
Agalsidase beta treatment is associated with improved quality of life in patients with Fabry disease: findings from the Fabry Registry. Genet Med (2010) 1.17
Current concepts and controversies in the treatment of alcoholic hepatitis. World J Gastroenterol (2006) 1.17
Signal transduction pathways involved in drug-induced liver injury. Handb Exp Pharmacol (2010) 1.16
Mechanisms of drug-induced liver disease. Clin Liver Dis (2007) 1.15
Acetaldehyde impairs mitochondrial glutathione transport in HepG2 cells through endoplasmic reticulum stress. Gastroenterology (2003) 1.14
Reduced glutathione depletion causes necrosis and sensitization to tumor necrosis factor-alpha-induced apoptosis in cultured mouse hepatocytes. Hepatology (2002) 1.13
Marked elevation in serum transaminases: an atypical presentation of choledocholithiasis. Am J Gastroenterol (2005) 1.12
Mitochondrial glutathione: features, regulation and role in disease. Biochim Biophys Acta (2012) 1.11
Hydrogen peroxide and redox modulation sensitize primary mouse hepatocytes to TNF-induced apoptosis. Free Radic Biol Med (2006) 1.11
Mechanism of staurosporine-induced apoptosis in murine hepatocytes. Am J Physiol Gastrointest Liver Physiol (2002) 1.10
Differences in betaine-homocysteine methyltransferase expression, endoplasmic reticulum stress response, and liver injury between alcohol-fed mice and rats. Hepatology (2010) 1.08
Regulation of drug-induced liver injury by signal transduction pathways: critical role of mitochondria. Trends Pharmacol Sci (2013) 1.07
Clinical perspectives on xenobiotic-induced hepatotoxicity. Drug Metab Rev (2004) 1.05
Mechanisms of protection by the betaine-homocysteine methyltransferase/betaine system in HepG2 cells and primary mouse hepatocytes. Hepatology (2007) 1.05
Haematological effects of interferon-beta-1a (Rebif) therapy in multiple sclerosis. Drug Saf (2004) 1.01
Regulation of H(2)O(2)-induced necrosis by PKC and AMP-activated kinase signaling in primary cultured hepatocytes. Am J Physiol Cell Physiol (2008) 1.01
Metabonomic investigation of liver profiles of nonpolar metabolites obtained from alcohol-dosed rats and mice using high mass accuracy MSn analysis. J Proteome Res (2010) 1.00
Mechanisms of pathogenesis in drug hepatotoxicity putting the stress on mitochondria. Mol Interv (2010) 1.00
Dynamic adaptation of liver mitochondria to chronic alcohol feeding in mice: biogenesis, remodeling, and functional alterations. J Biol Chem (2012) 0.99
Mechanisms of drug-induced liver injury. Clin Liver Dis (2013) 0.99
Role of cAMP-responsive element-binding protein (CREB)-regulated transcription coactivator 3 (CRTC3) in the initiation of mitochondrial biogenesis and stress response in liver cells. J Biol Chem (2011) 0.98
Usnic acid-induced necrosis of cultured mouse hepatocytes: inhibition of mitochondrial function and oxidative stress. Biochem Pharmacol (2004) 0.98
Glutathione depletion down-regulates tumor necrosis factor alpha-induced NF-kappaB activity via IkappaB kinase-dependent and -independent mechanisms. J Biol Chem (2007) 0.97
Effect of transgenic extrahepatic expression of betaine-homocysteine methyltransferase on alcohol or homocysteine-induced fatty liver. Alcohol Clin Exp Res (2008) 0.97
Avoiding idiosyncratic DILI: two is better than one. Hepatology (2013) 0.93
Mitochondrial GSH determines the toxic or therapeutic potential of superoxide scavenging in steatohepatitis. J Hepatol (2012) 0.93
Liver and skin histopathology in adults with acid sphingomyelinase deficiency (Niemann-Pick disease type B). Am J Surg Pathol (2012) 0.93
Follicular development induced by recombinant luteinizing hormone (LH) and follicle-stimulating hormone (FSH) in anovulatory women with LH and FSH deficiency: evidence of a threshold effect. Curr Med Res Opin (2008) 0.92
Current challenges and controversies in drug-induced liver injury. Drug Saf (2012) 0.90
Interstrain differences in liver injury and one-carbon metabolism in alcohol-fed mice. Hepatology (2012) 0.89
The clinical liver safety assessment best practices workshop: rationale, goals, accomplishments and the future. Drug Saf (2014) 0.87
How to protect against acetaminophen: don't ask for JUNK. Gastroenterology (2008) 0.87
Severe hepatotoxicity associated with the use of weight loss diet supplements containing ma huang or usnic acid. J Hepatol (2004) 0.87
Liver safety assessment in special populations (hepatitis B, C, and oncology trials). Drug Saf (2014) 0.86
Drug hepatotoxicity. Clin Liver Dis (2006) 0.86
Recombinant human luteinizing hormone, lutropin alfa, for the induction of follicular development and pregnancy in profoundly gonadotrophin-deficient women. Clin Endocrinol (Oxf) (2007) 0.85
Balancing benefit and risk of medicines: a systematic review and classification of available methodologies. Pharmacoepidemiol Drug Saf (2014) 0.84
Differential effect of gender on hepatic fat. Pediatr Radiol (2011) 0.83
Respiratory substrates regulate S-nitrosylation of mitochondrial proteins through a thiol-dependent pathway. Chem Res Toxicol (2014) 0.82
An overview of the GHMonitor, a registry of children treated with Saizen somatropin [recombinant hGH for injection]. Pediatr Endocrinol Rev (2005) 0.82
The risk of malignancy is not increased in patients with multiple sclerosis treated with subcutaneous interferon beta-la: analysis of data from clinical trial and post-marketing surveillance settings. Mult Scler (2011) 0.80
Investigation of chronic alcohol consumption in rodents via ultra-high-performance liquid chromatography-mass spectrometry based metabolite profiling. J Chromatogr A (2012) 0.79
Results from a 9-year Intensive Safety Surveillance Scheme (IS(3) ) in miglustat (Zavesca(®) )-treated patients. Pharmacoepidemiol Drug Saf (2015) 0.79
Benefit-risk assessment in a post-market setting: a case study integrating real-life experience into benefit-risk methodology. Pharmacoepidemiol Drug Saf (2014) 0.78
Genetic variation in UGT1A1 typical of Gilbert syndrome is associated with unconjugated hyperbilirubinemia in patients receiving tocilizumab. Pharmacogenet Genomics (2011) 0.78
Chelerythrine stimulates GSH transport by rat Mrp2 (Abcc2) expressed in canine kidney cells. Am J Physiol Gastrointest Liver Physiol (2003) 0.78
A murder mystery in the liver: who done it and how? J Clin Invest (2016) 0.76
The thiol sensitivity of glutathione transport in sidedness-sorted basolateral liver plasma membrane and in Oatp1-expressing HeLa cell membrane. Mol Pharmacol (2002) 0.75
Statin-induced hepatotoxicity. Gastroenterology (2004) 0.75
Liver injury associated with the beta-interferons for MS. Neurology (2004) 0.75
Did this drug cause my patient's hepatitis? Ann Intern Med (2003) 0.75